3-(二苯基甲氧基)哌啶 | 78503-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(二苯基甲氧基)哌啶
• 英文名称: 3-diphenylmethoxypiperidine
• 英文别名: Piperidin-3-yl-benzhydryl-ether；Piperidin-3-yl-benzhydryl-aether；3-(Diphenylmethoxy)piperidine；3-benzhydryloxypiperidine
• CAS: 78503-38-5
• 化学式: C₁₈H₂₁NO
• 分子量: 267.371
• InChiKey: ZVMFVQWWCVDATC-UHFFFAOYSA-N

物化性质

• 沸点：
  138-141 °C(Press: 0.04 Torr)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(二苯基甲氧基)哌啶 在 sodium hydroxide 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 4-(3-Benzhydryloxypiperidin-1-yl)butanoic acid
  参考文献：
  名称：

  GABA uptake inhibitors. Syntheses and structure—activity studies on GABA analogues containing diarylbutenyl and diarylmethoxyalkyl N-substituents

  摘要：

  A number of analogues of GABA or B-alanine containing 4,4-diphenyl-3-butenyl (DPB), benzhydryl ethyl ether (BEE), or benzhydryl propyl ether N-substituents have been synthesized and tested as inhibitors of synaptosomal GABA uptake. N-methylation of these analogues resulted in increased potency and reduced pKa II values of the reaction products 4a and 8a, respectively. Incorporation of the alkyl groups of the benzhydryl alkyl ether moieties of N-methyl-N-BEE-B-alanine (12), N-methyl-N-BEE-GABA (8a), or the benzhydryl propyl ether analogue of N-methyl-GABA (10) into the cyclized piperidine analogues gave the less active compounds 17, 18, and 19, respectively. This loss of in vitro activity was most pronounced for the GABA analogues 18 and 19. These results suggest that the basic character of the amino groups as well as the conformational flexibility of the spacer-arm connecting the amino acid 'heads' and the aromatic moieties of this class of GABA uptake inhibitors are factors of importance for GABA uptake affinity.

  DOI：

  10.1016/0223-5234(91)90214-8
• 作为产物：
  描述：

  3-羟基哌啶-1-羧酸甲酯 在 氢氧化钾 、 potassium carbonate 作用下， 以 甲醇 、 水 、 xylene 为溶剂， 反应 92.0h， 生成 3-(二苯基甲氧基)哌啶
  参考文献：
  名称：

  GABA uptake inhibitors. Syntheses and structure—activity studies on GABA analogues containing diarylbutenyl and diarylmethoxyalkyl N-substituents

  摘要：

  A number of analogues of GABA or B-alanine containing 4,4-diphenyl-3-butenyl (DPB), benzhydryl ethyl ether (BEE), or benzhydryl propyl ether N-substituents have been synthesized and tested as inhibitors of synaptosomal GABA uptake. N-methylation of these analogues resulted in increased potency and reduced pKa II values of the reaction products 4a and 8a, respectively. Incorporation of the alkyl groups of the benzhydryl alkyl ether moieties of N-methyl-N-BEE-B-alanine (12), N-methyl-N-BEE-GABA (8a), or the benzhydryl propyl ether analogue of N-methyl-GABA (10) into the cyclized piperidine analogues gave the less active compounds 17, 18, and 19, respectively. This loss of in vitro activity was most pronounced for the GABA analogues 18 and 19. These results suggest that the basic character of the amino groups as well as the conformational flexibility of the spacer-arm connecting the amino acid 'heads' and the aromatic moieties of this class of GABA uptake inhibitors are factors of importance for GABA uptake affinity.

  DOI：

  10.1016/0223-5234(91)90214-8

文献信息

• N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
  申请人：Ciba-Geigy Corporation

  公开号：US04261990A1

  公开（公告）日：1981-04-14

  N-(diphenylmethoxy-mono- or bicyclic-alkyleneiminoalkyl)-dicarboximides, e.g. those of the formula ##STR1## A=aliphatic or cycloaliphatic radical R,R'=H, alkyl, halogen or CF.sub.3 R"=H or both are ethylene q=2-4 and salts thereof are antiallergics and antiasthmatics.

  N-(二苯甲氧基单环或双环烷基亚胺基)-二羧酰亚胺，例如公式##STR1## A=脂肪或环脂肪基，R，R'=氢，烷基，卤素或CF.sub.3，R"=氢或两者均为乙烯，q=2-4，其盐为抗过敏和抗哮喘剂。
• Piperidine derivatives
  申请人：Pfizer Limited

  公开号：EP0350309A1

  公开（公告）日：1990-01-10

  The (3R,S)- or (3R)- form of a compound of the formula:- or a pharmaceutically acceptable salt thereof, wherein R1 is a group of the formula:- where each Y, which may be the same or different, is selected from the substituents hydrogen, halo and C1-C4 alkyl: X is -(CH2)2-, -CH=CH-, -CH2-S-, -CH2-0-, -S- or -O-; and R is a group of the formula:- wherein R2, R3, R4 and R5 are certain specified substituents. The compounds are useful in the treatment of diseases associated with altered motility and/or tone of smooth muscle.

  式中化合物的(3R,S)-或(3R)-形式：- 或其药学可接受盐，其中 R1 是式中的基团。 或其药学上可接受的盐，其中 R1 是式中的一个基团：- 其中每个 Y（可以相同或不同）选自取代基氢、卤代和 C1-C4 烷基：X是-(CH2)2-、-CH=CH-、-CH2-S-、-CH2-0-、-S-或-O-；R是式中的基团：- 其中 R2、R3、R4 和 R5 是某些特定的取代基。 这些化合物可用于治疗与平滑肌运动性和/或张力改变有关的疾病。
• FALCH, E.;KROGSGAARD-LARSEN, P., EUR. J. MED. CHEM., 26,(1991) N, C. 69-78
  作者：FALCH, E.、KROGSGAARD-LARSEN, P.

  DOI：——

  日期：——
• US4261990A
  申请人：——

  公开号：US4261990A

  公开（公告）日：1981-04-14
• US5089505A
  申请人：——

  公开号：US5089505A

  公开（公告）日：1992-02-18